Abstract:The farnesoid-x-receptor (FXR) and the G protein bile acid activated receptor (GPBAR)1 are two bile acid activated receptors highly expressed in entero-hepatic, immune, adipose and cardiovascular tissues. FXR and GPBAR1 are clinically validated targets in the treatment of metabolic disorders and FXR agonists are currently trialled in patients with non-alcoholic steato-hepatitis (NASH). Results of these trials, however, have raised concerns over safety and efficacy of selective FXR ligands suggesting that the development of novel agent designed to impact on multiple targets might have utility in the treatment of complex, multigenic, disorders. Harnessing on FXR and GPBAR1 agonists, several novel hybrid molecules have been developed, including dual FXR and GPBAR1 agonists and antagonists, while exploiting the flexibility of FXR agonists toward other nuclear receptors, dual FXR and peroxisome proliferators-activated receptors (PPARs) and liver-X-receptors (LXRs) and Pregnane-X-receptor (PXR) agonists have been reported. In addition, modifications of FXR agonists has led to the discovery of dual FXR agonists and fatty acid binding protein (FABP)1 and Leukotriene B4 hydrolase (LTB4H) inhibitors. The GPBAR1 binding site has also proven flexible to accommodate hybrid molecules functioning as GPBAR1 agonist and cysteinyl leukotriene receptor (CYSLTR)1 antagonists, as well as dual GPBAR1 agonists and retinoid-related orphan receptor (ROR)γt antagonists, dual GPBAR1 agonist and LXR antagonists and dual GPBAR1 agonists endowed with inhibitory activity on dipeptidyl peptidase 4 (DPP4). In this review we have revised the current landscape of FXR and GPBAR1 based hybrid agents focusing on their utility in the treatment of metabolic associated liver disorders.

Role of FXR in regulating bile acid homeostasis and relevance for human diseases.

Farnesoid X receptor modulators 2014-present: a patent review

Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities

Development of bile acid activated receptors hybrid molecules for the treatment of inflammatory and metabolic disorders

FXR: structures, biology, and drug development for NASH and fibrosis diseases

The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis

Discovery of farnesoid X receptor and its role in bile acid metabolism

Role of farnesoid X receptor in cholestasis

[On the Bile Acid Receptor FXR].

FXR Friend-ChIPs in the Enterohepatic System

Bile Acids and FXR: Novel Targets for Liver Diseases

Farnesoid X Receptor (FXR): Structures and Ligands.

Effects of farnesoid X receptor on the expression of the fatty acid synthetase and hepatic lipase

The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer

Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis

STRUCTURAL BASIS FOR BILE ACID BINDING AND ACTIVATION OF THE NUCLEAR RECEPTOR FXR

FXR,A Multifunctional Nuclear Receptor

Nuclear receptor FXR, bile acids and liver damage: Introducing the progressive familial intrahepatic cholestasis with FXR mutations

FXR Modulators for Enterohepatic and Metabolic Diseases.

The farnesoid X receptor: a novel drug target?

Hepatic FXR-FGF4 is required for bile acid homeostasis via an FGFR4-LRH-1 signal node under cholestatic stress